Clinical trials: Crohn's Diseases
Crohn Disease
Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease
The purpose of this study is to observe pediatric Crohn's Disease response to sargramostim in patients with or without steroid therapy at two possible dosage levels.
- Trial name
- NCT00206661
- Testing
- Sargramostim (Leukine)
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Inflammatory Bowel Diseases, Crohn Disease
Cost-effectiveness of TPMT Pharmacogenetics
The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT) genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel disease (IBD) in need of immune suppression.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- TOPIC (NCT00521950)
- Testing
- TPMT genotyping; Drug: azathioprine or 6-mercaptopurine, azathioprine (AZA) or 6-mercaptopurine (6-MP)
- Where
- 3 sites in Netherlands
- Volunteers
- 853 people
- Sponsor
- ZonMw: The Netherlands Organisation for Health Research and Development
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Crohn's Disease
Synbiotics and Post-op Crohn's Disease
Crohn's disease (CD) is a lifelong incurable condition that causes inflammation of the intestinal tract of humans. The exact cause of CD is unknown, but genetics, diet, and the gut microbiome are all thought to play a major role.
- Trial name
- NCT04804046
- Testing
- Synbiotic, Digestible Maltodextrin
- Where
- 5 sites in Canada
- Volunteers
- 4 people
- Sponsor
- University of Alberta
Crohns Disease
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
The study is being conducted to evaluate the pharmacokinetic parameters (Cmax, Tmax and AUC) of the new delayed release, lowered dose, 40 mg 6MP test formulation as compared to standard 6MP (100 mg Purinethol) in 12 patients with…
- Trial name
- NCT00774982
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Teva GTC
Crohn Disease
The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )
The purpose of this study is to determine if vitamin D as an adjuvant therapy can improve the outcome (i.e. fewer relapses) and the quality of life, including levels of physical activity, in children diagnosed Crohn's disease…
- Trial name
- ViDiPeC-2 (NCT03999580)
- Testing
- vitamin D3
- Where
- 7 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Jantchou Prevost
Crohn's Disease
Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease
This study is designed to explore mechanism of action of mongersen (GED-0301) 160 mg once daily in patients with active Crohn's Disease
- Trial name
- NCT02685683
- Testing
- GED-0301
- Where
- 2 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Celgene
Crohn Disease, Colitis, Ulcerative
Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe
The purpose of this survey is to describe Crohn's disease (CD) participants' as well as ulcerative colitis (UC) participants' preferences towards the attributes of treatment with advanced therapies for IBD, including safety and…
- Conditions
- Crohn Disease, Colitis, Ulcerative, Inflammatory Bowel Diseases
- Trial name
- NCT04597905
- Where
- France
- Volunteers
- 686 people
- Sponsor
- Takeda
IBD, Crohn Disease
The Nori Health App
A multicenter, randomized controlled trial with an embedded pilot and qualitative component to investigate the effects of the Nori Health app.
- Conditions
- IBD, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT05474742
- Testing
- The Nori Health app
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- UMC Utrecht
Crohn's Disease
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat moderate to severe inflammatory, nonstricturing, nonpenetrating Crohn's disease.
- Trial name
- NCT00267722
- Testing
- Visilizumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Facet Biotech
Perianal Crohns Disease
VirtuAl Technology to Improve the Management of Perianal Crohn's (VAMP) - PROSPECTIVE
Crohn's is an inflammatory condition that can affect any part of the gut. Over half a million people in the UK live with Crohn's disease and about a quarter will develop a fistula near their back passage.
- Trial name
- VAMP-PROSPECT (NCT06587646)
- Testing
- Virtual Examination under Anaeastehtic - 3D reconstruction imaging, Standard Care - Written MRI report
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are…
- Trial name
- CULTIVATE (NCT04173273)
- Testing
- Etrasimod
- Where
- 510 sites in United States, Argentina and 39 more
- Volunteers
- 379 people
- Sponsor
- Pfizer
Crohn Disease (CD)
Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease
MAINTAIN-POP is a Phase 2, randomised, double-blind, placebo-controlled, multicenter study of the impact of oral administration of EXL01 in the prevention of post-operative endoscopic recurrence of Crohn's disease after surgery.
- Trial name
- MAINTAIN-POP (NCT06925061)
- Where
- 12 sites in France
- Volunteers
- 80 people
- Sponsor
- Madeleine Bezault
Irritable Bowel Syndrome, Inflammatory Bowel Disease (IBD)
Cognition and Emotion in the SII and IBD
The study aims at showing that the susceptibility in the stress is more raised at the person affected digestive pathologies (SII or IBD) in forgiveness than healthy subjects.
- Conditions
- Irritable Bowel Syndrome, Inflammatory Bowel Disease (IBD), Crohn's Disease(CD), Ulcerative Colitis
- Trial name
- EMOTION (NCT01095042)
- Testing
- emotion
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Inflammatory Bowel Diseases, Crohn's Disease
Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)
The purpose of this study is to determine if the program that has been made to ease the transition of care for adolescent patients with IBD from pediatric gastroenterology to adult gastroenterology is effective to reduce the risk…
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT00360022
- Testing
- Joint visits
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt University Medical Center
Fistulizing Crohn's Disease
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24.
- Trial name
- Divergence2 (NCT03077412)
- Testing
- Filgotinib
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 57 people
- Sponsor
- Gilead Sciences
Inflammatory Bowel Diseases
Mitochondrial DAMPs as Mechanistic Biomarkers of Mucosal Inflammation in Crohn's Disease and Ulcerative Colitis
The MUSIC study is a multi-centre, longitudinal study set in the real world IBD clinical setting to investigate and develop a new biomarker approach that aims to inform both patients and clinicians of the current state of the…
- Trial name
- MUSIC (NCT04760964)
- Where
- 3 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- University of Edinburgh
Crohn Disease
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor [TNF] alpha, anti-integrin, and anti-interleukin [IL]-23 targeted…
- Trial name
- PATHFINDER (NCT05928039)
- Testing
- TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab
- Where
- 23 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University of Calgary
Fatigue, Inflammatory Bowel Disease
Metabolomic Markers of Fatigue in Inflammatory Bowel Disease
Fatigue is a common symptom and a leading concern in patients with inflammatory bowel disease (IBD) and often persists despite clinical and endoscopic remission.
- Conditions
- Fatigue, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT04191707
- Volunteers
- 18 people
- Sponsor
- Corporacion Parc Tauli
Inflammatory Bowel Disease, Crohn Disease
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
- Trial name
- NCT04331639
- Testing
- vitamin D3
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.